Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 29, 2012

View Archived Issues

Chugai Pharmaceutical reflects on milestones of 2011

Modified gold nanoparticles display potent anticoagulant activity

Phase II trial assesses safety paclitaxel/everolimus combination in advanced urothelial cancer

New cognition-enhancing serotonin 5-HT6 receptor antagonist discovered at Cephalon

AnaptysBio describes new antibodies targeting IL-17

Merck & Co. patents novel products with potential to prevent herpes zoster

Novel 5-lipoxygenase inhibitors disclosed by Ranbaxy Laboratories

Medexis reports new products with potential to treat cancer

New cyclopropylamine derivatives designed at Oryzon Genomics

Wakunaga and NeuGen Pharma present new agents for neurological disorders

Zalicus compounds show promise as therapies for absence seizures

Selventa enters new collaboration

Alimera Sciences and pSivida provide update on Iluvien

BioDelivery Sciences and FDA agree on BEMA-buprenorphine/naloxone development plan

Proteonomix gives update on UMK-121 study

Bioheart selects site for ANGEL trial

Phase III trials of 6-month anticancer depot begin in Japan

OncoSec initiates treatment in phase II trial in metastatic melanoma

Antisense Therapeutics to form joint venture for development of ATL-1102

Lundbeck acquires remaining rights to ischemic stroke treatment candidate

New RaQualia product set to enter clinical development

FDA revises labeling for statins

Samsung Biologics and Biogen Idec form joint venture

Abbott enters global agreement for novel JAK1 inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...